Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.
Zhanel GG, Dhami R, Baxter M, Wong M, Mirzanejad Y, Kosar J, Cervera C, Irfan N, Borgia S, Serebryanskyy A, Ariano R, Savoie M, Tascini C, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: borgia s. Expert Rev Anti Infect Ther. 2024 Sep 26:1-8. doi: 10.1080/14787210.2024.2405930. Online ahead of print. Expert Rev Anti Infect Ther. 2024. PMID: 39324660
How is ceftobiprole used in Canada: the CLEAR study final results.
Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, Dow G, Dube M, von den Baumen TR, Tascini C, Lee A, Chagla Z, Girouard G, Bourassa-Blanchette S, Wu M, Keynan Y, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: borgia s. Expert Rev Anti Infect Ther. 2024 Aug;22(8):681-688. doi: 10.1080/14787210.2024.2374280. Epub 2024 Jul 15. Expert Rev Anti Infect Ther. 2024. PMID: 39008122
Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.
Imsirovic H, Macphail G, Conway B, Fraser C, Borgia S, Smyth D, Wong A, Vachon ML, Webster D, Liu H, Feld J, Lee S, Cooper C; Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort Investigator Team. Imsirovic H, et al. Among authors: borgia s. J Viral Hepat. 2024 Nov;31(11):775-779. doi: 10.1111/jvh.13995. Epub 2024 Aug 12. J Viral Hepat. 2024. PMID: 39135466
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
Wedemeyer H, Di Marco V, Garcia-Retortillo M, Teti E, Fraser C, Morano Amado LE, Rodriguez-Tajes S, Acosta-López S, O'Loan J, Milella M, Buti M, Guerra-Veloz MF, Ramji A, Fenech M, Martins A, Borgia SM, Vanstraelen K, Mertens M, Hernández C, Ntalla I, Ramroth H, Milligan S. Wedemeyer H, et al. Among authors: borgia sm. Viruses. 2022 Nov 11;14(11):2493. doi: 10.3390/v14112493. Viruses. 2022. PMID: 36423102 Free PMC article.
Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial.
Lau VI, Fowler R, Pinto R, Tremblay A, Borgia S, Carrier FM, Cheng MP, Conly J, Costiniuk CT, Daley P, Duan E, Durand M, Fontela PS, Farjou G, Fralick M, Geagea A, Grant J, Keynan Y, Khwaja K, Lee N, Lee TC, Lim R, O'Neil CR, Papenburg J, Semret M, Silverman M, Sligl W, Somayaji R, Tan DHS, Tsang JLY, Weatherald J, Yansouni CP, Zarychanski R, Murthy S; E-CATCO authors, AMMI Clinical Research Network and Canadian Critical Care Trials Group. Lau VI, et al. Among authors: borgia s. CMAJ Open. 2022 Sep 6;10(3):E807-E817. doi: 10.9778/cmajo.20220077. Print 2022 Jul-Sep. CMAJ Open. 2022. PMID: 36199248 Free PMC article. Clinical Trial.
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, Cavayas YA, Chagnon N, Cheng MP, Conly J, Costiniuk C, Daley P, Daneman N, Douglas J, Downey C, Duan E, Duceppe E, Durand M, English S, Farjou G, Fera E, Fontela P, Fowler R, Fralick M, Geagea A, Grant J, Harrison LB, Havey T, Hoang H, Kelly LE, Keynan Y, Khwaja K, Klein G, Klein M, Kolan C, Kronfli N, Lamontagne F, Lau R, Fralick M, Lee TC, Lee N, Lim R, Longo S, Lostun A, MacIntyre E, Malhamé I, Mangof K, McGuinty M, Mergler S, Munan MP, Murthy S, O'Neil C, Ovakim D, Papenburg J, Parhar K, Parvathy SN, Patel C, Perez-Patrigeon S, Pinto R, Rajakumaran S, Rishu A, Roba-Oshin M, Rushton M, Saleem M, Salvadori M, Scherr K, Schwartz K, Semret M, Silverman M, Singh A, Sligl W, Smith S, Somayaji R, Tan DHS, Tobin S, Todd M, Tran TV, Tremblay A, Tsang J, Turgeon A, Vakil E, Weatherald J, Yansouni C, Zarychanski R; Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Ali K, et al. Among authors: borgia s. CMAJ. 2022 Feb 22;194(7):E242-E251. doi: 10.1503/cmaj.211698. Epub 2022 Jan 19. CMAJ. 2022. PMID: 35045989 Free PMC article. Clinical Trial.
45 results